Home › Companies › SEPN

Septerna

Market cap $1.90B 47.5M shares (10-Q, Nov 4, 2026) × $40.02 close Nov 17, 2026

Most recent annual filing: 2026-03-09

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. BIOSECURE Act restricted supplier listDec 18, 2026BIOSECURE Act restricted supplier list, Dec 18, 2026, routine
  2. SEP-479 Ph1 topline1Q 2027SEP-479 Ph1 topline, 1Q 2027, thesis-defining
  3. SEP-204 Ph1 start1Q 2027SEP-204 Ph1 start, 1Q 2027, notable
  4. Immunovant IMVT-1402 pivotal readout2027Immunovant IMVT-1402 pivotal readout, 2027, notable
  5. BridgeBio encaleret PDUFA dateMay 8, 2027BridgeBio encaleret PDUFA date, May 8, 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Technology platforms

Native Complex Platform · Novo Nordisk

Proprietary GPCR drug discovery platform that replicates the natural structure, function, and dynamics of GPCRs outside of cells at industrial scale. Enables isolation, purification, and reconstitution of full-length GPCR proteins in ternary complexes with ligands and transducer proteins in a lipid bilayer. Supports structure-based drug design of oral small molecule agonists, antagonists, and allosteric modulators across endocrinology, immunology, inflammation, and metabolic diseases. Used both in wholly-owned programs and in collaboration with Novo Nordisk for GLP-1, GIP, and glucagon receptor-targeted metabolic disease programs.

Targets: GLP-1 receptor, GIP receptor, glucagon receptor, MRGPRX2, PTH1R, TSHR, GLP-1R, GIPR, GCGR

Native Complex Platform

Industrialized GPCR drug discovery platform enabling isolation of fully functional GPCR proteins in native lipid bilayer complexes; supports high-resolution structure determination, screening of billions of compounds, and iterative structure-based drug design; focus on difficult-to-drug GPCRs across endocrinology, immunology/inflammation, neurology, women's health, cardiovascular, respiratory, and metabolic diseases

Native Complex Platform · Novo

Proprietary industrial-scale GPCR drug discovery platform that replicates the natural structure, function, and dynamics of GPCRs outside of cells, enabling isolation, purification, and reconstitution of full-length GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer; supports structure-based drug design for agonists, antagonists, and allosteric modulators across endocrinology, immunology, inflammation, and metabolic diseases

Targets: GLP-1 receptor, GIP receptor, glucagon receptor

Discontinued (1)

Capital (as filed)

Cash
$167M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$311M Sep 30, 2026
Long-term investments
$86.6M Sep 30, 2026
Operating cash flow
−$13.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$565M cash, runway mid-2029 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Septerna, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Septerna (SEPN) - Scientific Deep Dive for SEP-479, SEP-204 and Pipeline Products Septerna's EV already prices in SEP-479 working before any human PD data, and both prior oral PTH1R agonists failed in the clinic, making the risk/reward unattractive at current levels.
  2. Watch UPDATE: Septerna (SEPN) - Everyone Sold the Jump Q1 2027 readout remains on schedule but the stock is now ~11% above the probability-weighted fair value and near its 52-week high, with insiders and smart money selling into strength, making the watch stance unchanged.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (18)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 9, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)